Search company, investor...
Search

Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

1

About John Burd

John Burd Headquarters Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest John Burd News

09:38 EDT Lysulin Looks to Expand U.S. Retail Outlets for Blood Sugar Supplement

Aug 26, 2022

News provided by Share this article Lysulin Promotes Healthy Blood Sugar, A1C, and Insulin Function BOCA RATON, Fla., Aug. 26, 2022 /PRNewswire/ -- Lysulin, a blood sugar support dietary supplement, is now available in the U.S. "Lysulin is a patented vegan formula that provides blood sugar support in three ways," said John Burd, CEO of Lysulin, Inc., a health and wellness company in San Diego. "Lysulin helps maintain healthy blood glucose, A1C, and insulin function. Lysulin products include: Burd said healthy blood glucose levels are important to everyone's well-being. "Lysulin is the only blood sugar supplement supported by clinical studies," Burd said. "Our patented formula has three powerful ingredients -- Lysine, Zinc, and Vitamin C. We used precise amounts of these ingredients to ensure the effectiveness of Lysulin." Burd said clinical studies show Lysine and Vitamin C help maintain healthy blood sugar levels. "Zinc provides nutritional support for people with poor insulin function," he added. Millions of people have excess sugar in their bloodstream, which can have adverse effects on the body's organs. "Your doctor routinely checks your blood sugar levels," Burd said. "A normal A1C result falls below 5.7 percent." Burd, a scientist and biochemist, said a 9 percent A1C increases risks to the kidneys, eyes, and neuropathy. "More consumers today are seeking alternative remedies, such as Lysulin, which is a cost-effective dietary supplement without a prescription or side effects," said Burd, who is also the founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring systems. To reach consumers, Lysulin plans to add more retail outlets. Next month, Lysulin's team will introduce its products to buyers from large and small retail chains at ECRM's "Vitamin, Weight Loss, and Sports Nutrition Program." ECRM brings buyers and brands with new products together for private one-on-one virtual meetings. Buyers attending the ECRM event represent regional and national food, drug, and mass health chains. "ECRM allows us the opportunity to meet with some of the most sought-after retailers in less than a week," he added. To purchase Lysulin products, visit Lysulin.com . Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please check with your doctor. Media Contact:

John Burd Investments

1 Investments

John Burd has made 1 investments. Their latest investment was in Alertgy as part of their Seed on January 1, 2019.

CBI Logo

John Burd Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/2/2019

Seed

Alertgy

$1.2M

Yes

2

Date

1/2/2019

Round

Seed

Company

Alertgy

Amount

$1.2M

New?

Yes

Co-Investors

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.